Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...

Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says author ...

Losing weight with the help of a prescription weight loss drug continues to increase in popularity. According to recent KFF polls, about one in eight U.S. adults takes a GLP-1 medication for ...

The Guardian reported on the 7th that research has found weight loss injections like Wegovy can be produced for as little as $3 per month. The report states that if semaglutide, the active ingredient ...

Your doctor will help you decide which form, pill or injection, of Wegovy is best for you. It may depend on your medical history, which dosing schedule fits your lifestyle better, and how comfortable ...

Downside to dropping pounds? The new pill form of popular GLP-1 drugs contains a compound that could cause troubling side ...

By Stine Jacobsen and Maggie Fick COPENHAGEN, March 9 (Reuters) - Novo Nordisk said on Monday it will sell its blockbuster Wegovy and Ozempic drugs through the U.S. telehealth company Hims & Hers ...

Add Yahoo as a preferred source to see more of our stories on Google. Now, oral GLP-1s for weight loss are available. If you’ve been using an injectable GLP-1 like Wegovy and are interested in ...

Novo Nordisk has signed an agreement with Hims & Hers Health that will allow the telehealth provider to offer FDA‑approved versions of Ozempic and Wegovy at self‑pay prices comparable to other digital ...

Unaided awareness rose sharply following approval. In February 2026, 60% of PCPs and 78% of endocrinologists cited the Wegovy pill as a top-of-mind weight loss therapy--up from just 14% and 11%, ...

The Danish drugmaker said it plans to offer the medicines for $675 per month starting in January 2027, representing a 50% reduction in price for Wegovy and a 35% reduction for Ozempic. Novo Nordisk ...

Battling to regain its market share over rival Eli Lilly, Novo Nordisk announced Tuesday that it will reduce the list prices of its popular weight loss drug Wegovy and diabetes drugs Ozempic and ...